Divis Labs jumps 7 per cent: these 3 mutual funds set to gain the most - do you hold any?
In the last five years, the API major has achieved compound earnings per share (EPS) growth of 22 per cent per year, which is amazing.
The Indian stock market has been on an upward trajectory for the past seven days. On Wednesday, the index continued its winning streak and is trading up by 0.25 per cent. The majority of the sectors are seen trading in the green, and the show-stopper for the day is Nifty Pharma, with all its constituents trading in green.
One stock, in particular, is racing towards its upper circuit limit of 10 per cent, and that is Divis Laboratories.
Divis Laboratories is a company that manufactures and sells generic active pharmaceutical ingredients (APIs) and intermediates, and nutraceutical ingredients in India, the United States, Asia, Europe, and internationally. The stock has skyrocketed over 7 per cent with an astonishing surge in total traded volumes, which is more than a fourfold rise when compared to its 10-day average volume. The stock has been a tepid performer over the last one year, declining nearly 30 per cent, but with Wednesday’s up-move, it is in the pink of health, and it has delivered a positive return of 12.61 per cent in the last one-month.
The loyal shareholders and mutual funds that hold this stock in their portfolio stand to benefit the most from this upsurge in the stock of Divis Laboratories. Let's take a look at the top three mutual fund schemes that benefit the most from this upsurge.
SBI Focused Equity Fund Growth holds 4,095,143 shares of Divis Laboratories, with an AUM size of Rs 26,573.19 crore and a percentage of holding of total AUM for this stock stands at 4.35 per cent. In March 2023, this scheme added 160,895 shares, which translates into a change of 4.09 per cent MoM.
SBI Large and Midcap Fund Regular IDCW-P holds 830,000 shares of Divis Laboratories, which translates into 2.38 per cent of the total AUM of the scheme. On an MoM basis, net shares addition jumped 76.60 per cent.
SBI Small Cap Fund Regular Plan Growth holds 384,704 shares of Divis Laboratories, which translates into 0.70 per cent of the total AUM of the scheme. On an MoM basis, net shares addition jumped 63.99 per cent.
In the last five years, the API major has achieved compound earnings per share (EPS) growth of 22 per cent per year, which is amazing.
In conclusion, Divis Laboratories is a stock that has seen a phenomenal surge in its stock price and trading volume on Wednesday. Mutual fund schemes that hold this stock in their portfolio stand to benefit the most from this upsurge. The loyal shareholders of Divis Laboratories can sit back and enjoy the benefits of their investment in this stock.